Aceglutamide CAS 2490-97-3

This substance has the effect of reducing blood ammonia. Related research experiments have shown that it is distributed in various parts of the human body, especially in renal tubular cells, and decomposes ammonia in the blood into acetyl glutamate. Ammonia in the blood is excreted through renal tubular cells.

In addition, the compound also has a detoxification mechanism. After entering the human body, it will pass through the blood-brain barrier and decompose glutamate, which can directly participate in the information transmission process of the central nervous system. However, other substances decomposed can inhibit the excitability of glutamate. These two substances compete with each other and can effectively improve nerve cells, achieving the effect of improving brain function.

This compound can be used to treat cerebral embolism and motor dysfunction. Relevant medical experimental data shows that it has the effect of promoting cell growth, and therefore can be used as a nutritional support material during high-intensity training recovery processes. This compound can cross the blood-brain barrier, break down into glutamate and gamma aminobutyric acid (GABA), improve neuronal metabolism, and maintain good stress function. In clinical practice, it is commonly used for severe neurological disorders such as traumatic coma, neurosurgical coma, and hepatic coma.

Promoting neurological function recovery: For motor dysfunction caused by neurological injuries such as hemiplegia, high paraplegia, and sequelae of infantile paralysis, this substance can help promote neurological function recovery and improve patients' motor abilities.
Relieve neuropathic pain and headache: This substance can also be used to treat symptoms such as neuropathic headache and lower back pain, by regulating neurotransmitter levels to alleviate patient pain.

Main indications: This product is mainly used to promote the recovery of comatose patients after neurosurgery surgery (such as brain tumors, traumatic brain injury, cerebrovascular disease, etc.), brain trauma, liver coma, hemiplegia, high paraplegia, neuroma, neuropathic headache, and lower back pain. Coma, memory and thinking disorders caused by various reasons such as intellectual disability, memory impairment, sequelae of infantile paralysis, and sequelae of mental disorders caused by drugs such as blood defense 846 (such as carbon monoxide poisoning, acute alcohol and drug poisoning, acute purulent meningitis, viral encephalitis, hepatic encephalopathy, pulmonary encephalopathy, electric shock injury, etc.).

Memory decline in the elderly and memory decline after cerebrovascular disease. Adjuvant treatment for elderly brain function decline includes chronic mental illness, geriatric psychiatric disorder syndrome, and depression. In psychiatric clinical practice, this product is often administered intravenously in combination with other drugs to improve cellular metabolism and nutritional status.

The literature report on epidemic encephalitis B observed the efficacy of the combination therapy of ribavirin and acetanilide in the treatment of encephalitis B. The cases were divided into two groups, and the two groups were basically the same in terms of gender, age, clinical type, and start date of treatment, which were comparable. Both groups received comprehensive treatment such as cooling, expectorant, sedation, dehydration, reducing intracranial pressure, fluid replacement, and infection prevention. In addition to comprehensive treatment, the treatment group received ribavirin injection at a dose of 15mg/kg per day and acetanilide at a dose of 0.02g/kg per day.

Both drugs were added to 10% glucose solution for intravenous infusion until the 10th day of illness, with an average duration of 5.7 days. The efficacy evaluation criteria are: cure: disappearance of symptoms and signs, no recovery period symptoms; effective: symptoms. And the physical signs have improved, with varying degrees of recovery symptoms remaining. The treatment group had a shorter time in terms of fever reduction, consciousness recovery, seizure cessation, and disappearance of cervical resistance compared to the control group. The incidence of central respiratory failure was 17.9% in the treatment group and 43.3% in the control group, with a significant difference between the two groups (x2=4.39, p<0.05).

The incidence of respiratory failure in the treatment group was significantly lower than that in the control group. In the treatment group, 20 cases were cured with a cure rate of 71.4%, 6 cases were effective, 2 cases were ineffective, and the total effective rate was 92.8%; In the control group, 13 cases were cured with a cure rate of 43.3%, 11 cases were effective, 6 cases were ineffective, and the total effective rate was 80%. There was a significant difference in the cure rate between the two groups (x2=4.66, p<0.05), while there was no significant difference in the total effective rate between the two groups (x2=1.08, p>0.05).

The early combined use of virazole and acetylglutamine in the treatment of Japanese encephalitis can control the worsening of the condition, improve brain function, promote fever reduction, clear consciousness, reduce the incidence and mortality of central respiratory failure, and increase the cure rate. The combination of two drugs has not yet shown significant aceglutamide side effects and can be used as one of the treatment methods for Japanese encephalitis.

In the clinical efficacy report of using acetylglutamine to rescue 30 cases of fluoride poisoning, a 1:5000 potassium permanganate solution was routinely used for gastric lavage, and acetylglutamine was immediately administered at a rate of 0.1-0.3/day, divided into 1-2 intravenous drops, for a total of 7 days or stopped after the child became conscious and the convulsions stopped. Simultaneously use dexamethasone, a large amount of vitamin C, phosphatidylcholine or brain active hormone, and energy mixture to protect organ function. Among all cases, 20 were cured, 8 were effective, and 2 had sequelae, manifested as spasticity and cerebral palsy with intellectual disability.

Those who died or survived with severe sequelae were children who had ingested large amounts of medication, young children, and those who were unable to use acetylglutamine immediately. The mechanism of action for treating fluoride poisoning is because acetylglutamine has a similar structure to this type of toxin. Acetylglutamine produces amide genes in the body or competition with fluoroacetic acid produced by sodium fluoroacetate to achieve detoxification. At the same time, it has the effects of improving neuronal metabolism, maintaining neural stress function, etc., thus reducing the occurrence of neurological sequelae.

The successful treatment of two cases of fluoroacetamide poisoning with acetylglutamine demonstrates that the treatment of fluoroacetamide poisoning with acetylglutamine involves the addition of an acetamide group (- CH2CONH2) in the chemical structure of acetylglutamine, which is similar to the chemical structure of acetamide. Clinical application has confirmed definite therapeutic effects. Due to the fact that most primary hospitals do not have acetamide drugs, when encountering fluoroacetamide poisoning, acetyl glutamine can be used as a substitute for treatment.

Brain hypoplasia was treated with scalp acupuncture combined with acupoint injection for cerebrovascular disease complicated with intellectual disability. Method: 74 patients were randomly divided into two groups. The treatment group consisted of 40 cases, who were treated with scalp acupuncture for the Zhisan needle and the Sishen needle, and were also injected with acetylglutamine and furosemide at acupoints such as Baihui. 34 cases in the control group were treated with intravenous infusion of 20mL of Naohuo Su and 0.9% sodium chloride injection, and the therapeutic effects of the two groups were compared and observed.

The effective rate in the treatment group was 95.0%, while the total effective rate in the control group was 85.3%. There was a significant difference between the two groups (p<0.05). Conclusion: The combination of scalp acupuncture and acupoint injection therapy has the effects of awakening the brain and opening the orifices, strengthening the brain and marrow, improving brain cell vitality, and enhancing brain function. It has a definite therapeutic effect on treating cerebrovascular disease complicated with intellectual disability. 50 cases of cerebral hypoplasia were treated with head acupoint injection of acetylglutamine and furothiamine, with good therapeutic effects.

Initially, scalp acupuncture was used to treat sequelae of brain disease, and later alternating treatment with scalp acupuncture and water acupuncture (acetylglutamine and furothiamine) was tried, and it was found that the latter had better therapeutic effects than the former. Immediately switched to using water needles instead of scalp needles to treat this disease, resulting in improved efficacy compared to before. From the analysis of the relationship between treatment outcomes and age, the younger the age, the better the therapeutic effect. Therefore, aceglutamide is believed that early treatment is appropriate for cerebral hypoplasia. Acetylglutamide and furosemide head acupoint injection therapy for cerebral hypoplasia showed a significant effect of 74%, an effective rate of 14%, and a total effective rate of 88%.